Overexpression of long noncoding RNA PTPRG-AS1 is associated with poor prognosis in epithelial ovarian cancer

Abstract

SUMMARY OBJECTIVE Long noncoding RNAs (lncRNAs) have been shown to play a critical role in tumor progression. Abnormal expression of LncRNA PTPRG antisense RNA 1 (PTPRG-AS1) has been reported in several tumors. Hence, we aimed to determine the expression and clinical significance of PTPRG-AS1 in epithelial ovarian cancer (EOC) patients. METHODS The expressions of PTPRG-AS1 were assessed in 184 pairs of EOC tumor specimens and adjacent normal tissues. The levels of target lncRNAs and GAPDH were examined using standard SYBR-Green methods. The relationships between the expressions of PTPRG-AS1 and the clinicopathological features were analyzed using the chi-square test. Multivariate analysis using the Cox proportional hazards model was performed to assess the prognostic value of PTPRG-AS1 in EOC patients. RESULTS We confirmed that the expressions of PTPRG-AS1 were distinctly higher in the EOC tissue compared with the adjacent non-tumor specimens (p < 0.01). Higher levels of PTPRG-AS1 in EOC patients were associated with advanced FIGO stage (p = 0.005), grade (p = 0.006), and distant metastasis (p = 0.005). Survival analyses revealed that patients with high expressions of PTPRG-AS1 had a distinctly decreased overall survival (p = 0.0029) and disease-free survival (p = 0.0009) compared with those with low expressions of PTPRG-AS1. Multivariate assays indicated that PTPRG-AS1 expression was an independent prognostic factor for both overall survival and disease-free survival in EOC (Both p < 0.05). CONCLUSIONS Our study suggests that PTPRG-AS1 may serve as a novel prognostic biomarker for EOC patients.

LncRNA PTPRG-AS1 Promotes the Metastasis of Hepatocellular Carcinoma by Enhancing YWHAG

“…Studies have indicated that the lncRNAs, MIAT [ 42 ], GABPB1 [ 43 ], and PDPK2P [ 44 ] influence tumor progression in HCC. Additionally, research revealed a relationship between PTPRG-AS1 and epithelial ovarian cancer [ 27 ] or osteosarcoma [ 45 ]. However, whether PTPRG-AS1 participates in the tumor progression of HCC has not been investigated.…”

“…LncRNA PTPRG antisense RNA 1 (PTPRG-AS1), a rarely reported novel lncRNA, was identified as an abnormal expression for the first time in breast cancer by Mostafa et al [ 26 ]. Subsequent experiment demonstrated that the PTPRG-AS1 expression were dramatically higher in epithelial ovarian cancer (EOC) tissues and may serve as a novel molecular marker for EOC patients [ 27 ]. Functional experiments suggest PTPRG-AS1 acts as a miRNA “sponge” to regulated protein regulator of cytokinesis 1 (PRC1) in nasopharyngeal carcinoma [ 28 ].…”

The role of receptor‐type protein tyrosine phosphatases in cancer

“…104 PTPRG-AS1 is overexpressed in epithelial ovarian cancer (EOC) tissues and acts as an oncogene. 105 It downregulates the expression level of miR-545-3p and thus increases HDAC4 to aggravate the malignancy of EOC. 106 PTPRG-AS1 has a similar effect in HCC.…”

The transcription factor ZEB1 mediates the progression of epithelial ovarian cancer by promoting the transcription of CircANKRD17

“…Epithelial ovarian cancer (EOC) accounts for 85%-90% of malignant ovarian tumors. [1,2] Patients in an early stage have no obvious symptoms; however, tumor metastasis is extremely likely to occur in the advanced stages of EOC. [3] Even though various treatment methods have improved, the survival rate of patients with EOC has not improved significantly.…”